This is the first update to the original CTS communication distributed on July 6th. As previously communicated, all CTS healthcare partners will remain on the Grifols ZIKV clinical trial until at least the end of October 2018, which coincides with the end of the WNV season.
Check out the Communication page for the complete details on the NAT ZIKV test update or by clicking the link: Communications
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
CTS was recently notified that one of the tubes listed in the Sample Acceptability document...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
On September 14, 2020, our Phoenix laboratory began performing a portion of our alternate donor anti...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...